Overview

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Status:
Not yet recruiting
Trial end date:
2025-09-10
Target enrollment:
Participant gender:
Summary
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company